FDA Implements BsUFA III to Expedite Biosimilar Review
Securing Stable Funding and Reducing Regulatory Uncertainty
The U.S. Food and Drug Administration (FDA) is fully implementing the Third Biosimilar User Fee Act (BsUFA III) to streamline the biosimilar review process and accelerate approvals. This reauthorization, effective for fiscal years 2023 through 2027, establishes annual user fee targets ranging from approximately $48.7 million (FY2024) to $51 million (FY2025). With a more stable funding stream, the FDA can expand its review staff and modernize its information technology (IT) infrastructure. This serves as a crucial mechanism to minimize the risk of regulatory delays, enabling developers to establish commercialization strategies based on predictable timelines.
Accelerating Development and Reducing Costs Through Meeting Structure Reform
BsUFA III revolutionizes the meeting structure for Biological Product Development (BPD) to enhance communication between developers and the FDA. Specifically, it introduces 'Type 2a meetings,' short, focused meetings designed to address urgent issues in specific areas, significantly reducing review wait times. Additionally, the requirement to submit preliminary comparative analysis data when applying for a 'Biosimilar Initial Advisory (BIA) meeting' has been eliminated, substantially reducing the administrative burden on developers. This enhanced communication efficiency accelerates developers' decision-making processes, prevents unnecessary clinical trial design changes, and ultimately contributes to cost savings.
Regulatory Science Pilot Program and Clinical Trial Simplification
A key feature of this amendment is the formal introduction of the Regulatory Science Pilot Program, which strengthens research support. This program aims to improve the methodologies for demonstrating the safety of interchangeable biosimilars and to leverage in-vitro and in-silico models to replace unnecessary large-scale clinical trials. This provides developers with the institutional basis to shorten or eliminate the comparative clinical trial phase with the reference drug, which is often costly. Ultimately, this has a positive impact by strengthening the scientific basis for providing patients with faster and more affordable treatments.
Driving Growth in the Global Biosimilar Market
With the global biosimilar market expected to reach approximately $32.9 billion to $41.97 billion by 2025, the successful implementation of BsUFA III is expected to further accelerate market growth. Leading developers such as Celltrion (068270), Samsung Bioepis, Sandoz (SDZ), and Coherus (CHRS) will be able to secure timely launch capabilities in a standardized regulatory environment as originator drug patents expire. In particular, with lower barriers to entry in the U.S. market, biosimilars are expected to penetrate the market more rapidly, leveraging their price competitiveness compared to originator biologics. As a result, this reauthorization provides a win-win structure for both biotech companies seeking to improve capital efficiency and the healthcare market seeking reasonable drug prices.
The full implementation of BsUFA III serves as a key driver in promoting capital inflows by increasing the regulatory predictability of the global biosimilar market, which is currently valued at approximately $32.9 billion in 2025. In the short term, the newly established Type 2a meetings and the relaxed BIA meeting regulations are expected to immediately reduce development timelines and costs during the pre-clinical and IND stages. In the medium to long term, the activation of in-vitro and in-silico models through the Regulatory Science Pilot Program is expected to significantly reduce costs in Phase 1 and Phase 3 clinical trials by enabling the omission of traditional comparative clinical trials. As a result, leading biosimilar developers such as Celltrion (068270), Samsung Bioepis, and Sandoz (SDZ) will be able to gain a competitive advantage in timely commercialization when originator drug patents expire. The shortened market entry time due to regulatory improvements will accelerate the capital recovery cycle for the entire biosimilar ecosystem, expanding early exit opportunities for venture capital firms.
Source: FDA Drug Approvals (rss)
http://www.fda.gov/industry/biosimilar-user-fee-amendments/bsufa-iii-fiscal-years-2023-2027